Anzeige
Mehr »
Sonntag, 02.11.2025 - Börsentäglich über 12.000 News
Der menschliche Genius hinter den Maschinen: Telescope Innovations und der Aufstieg der autonomen Wissenschaft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A119KH | ISIN: IL0011319527 | Ticker-Symbol: 1BT
Tradegate
29.10.25 | 20:06
0,910 Euro
-0,55 % -0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENLIVEX THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ENLIVEX THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,9250,96501.11.
0,8950,93531.10.

Aktuelle News zur ENLIVEX THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEnlivex Therapeutics Ltd: Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 20251
03.10.RedChip Companies, Inc.: Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV273ORLANDO, FLORIDA / ACCESS Newswire / October 3, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Lantern Pharma, Inc. (Nasdaq:LTRN) on the RedChip Small...
► Artikel lesen
ENLIVEX THERAPEUTICS Aktie jetzt für 0€ handeln
25.09.Enlivex Therapeutics beraumt jährliche Hauptversammlung für 10. November an1
25.09.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
19.09.RedChip Companies, Inc.: Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV228ORLANDO, FLORIDA / ACCESS Newswire / September 19, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the...
► Artikel lesen
15.09.H.C. Wainwright reiterates Buy rating on Enlivex Therapeutics stock at $71
09.09.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
29.08.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer2
18.08.Enlivex stock soars after positive knee osteoarthritis trial data17
18.08.Enlivex Therapeutics Ltd: Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis297ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee...
► Artikel lesen
15.08.Stocks Moving Premarket: Perfect Moment, KULR Technology, Enlivex Therapeutics, Origin Materials, And Other Gainers & Losers653SANTA CLARA (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
14.08.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer9
28.07.Enlivex Therapeutics Ltd: Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data17
28.07.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
13.06.RedChip Companies, Inc.: Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV404ORLANDO, FL / ACCESS Newswire / June 13, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics (NASDAQ:ENLV) and Foremost Clean Energy (Nasdaq:FMST) on the RedChip Small Stocks, Big...
► Artikel lesen
10.06.Enlivex Therapeutics Ltd: Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology10
30.05.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer3
21.04.Enlivex Therapeutics Ltd: Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis307Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
► Artikel lesen
03.04.Enlivex Therapeutics Ltd: Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis197Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globallyTMJ...
► Artikel lesen
03.03.Enlivex Therapeutics Ltd: Enlivex Announces Positive Interim Data - Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis297Nes-Ziona, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1